II

Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

Saturday, December 4, 2021 - 1:00pm

SYDNEY, Dec. 4, 2021 /PRNewswire/ --Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).

Key Points: 
  • SYDNEY, Dec. 4, 2021 /PRNewswire/ --Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).
  • Kazia expects to receive a final clinical study report in 1Q CY2022 and intends to seek publication of these data in a peer-reviewed scientific journal thereafter.
  • Kazia CEO, Dr James Garner, commented, "We are delighted to report positive final data from the completed phase II study of paxalisib.
  • Consistent with these objectives, the primary objective of the study was to evaluate the safety and tolerability of paxalisib in patients with newly diagnosed glioblastoma.

Histone Deacetylase 6 (HDAC 6) Inhibitors Pipeline Market Report 2021: Insights on 10+ Companies and 10+ Pipeline Drugs in the Landscape - ResearchAndMarkets.com

Friday, December 3, 2021 - 12:06pm

This "Histone Deacetylase 6 (HDAC 6) inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Histone Deacetylase 6 (HDAC 6) inhibitors pipeline landscape.

Key Points: 
  • This "Histone Deacetylase 6 (HDAC 6) inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Histone Deacetylase 6 (HDAC 6) inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Histone Deacetylase 6 (HDAC 6) inhibitors R&D.
  • The companies which have their Histone Deacetylase 6 (HDAC 6) inhibitors drug candidates in the most advanced stage, i.e.
  • Histone Deacetylase 6 (HDAC 6) inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

Friday, December 3, 2021 - 6:30am

In the ARASENS trial, darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to placebo, docetaxel and ADT.

Key Points: 
  • In the ARASENS trial, darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to placebo, docetaxel and ADT.
  • The results show that darolutamide, a compound discovered by Orions scientists, in combination with docetaxel and androgen deprivation therapy improves overall survival for patients with metastatic hormone-sensitive prostate cancer.
  • Men with metastatic hormone-sensitive prostate cancer (mHSPC) will start their treatment with hormone therapy, such as ADT, androgen receptor inhibitor (ARi) plus ADT or a combination of the chemotherapy docetaxel and ADT.
  • Despite this treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival.

TMC THE METALS COMPANY INC. (NASDAQ: TMC) SHAREHOLDER CLASS ACTION FILING DEADLINE- Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against TMC the metals company Inc.

Thursday, December 2, 2021 - 7:15pm

If you purchased TMC securities, and/or would like to discuss your legal rights and options, please visit TMC the metals company Inc Shareholder Class Action Lawsuit or contact Joe Seidman toll free at (877) 779-1414 or seidman@bernlieb.com .

Key Points: 
  • If you purchased TMC securities, and/or would like to discuss your legal rights and options, please visit TMC the metals company Inc Shareholder Class Action Lawsuit or contact Joe Seidman toll free at (877) 779-1414 or seidman@bernlieb.com .
  • If you wish to serve as lead plaintiff, you must move the Court no later than December 27, 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Emerald Health Pharmaceuticals’ Novel Drug Candidate Demonstrates Significant Anti-inflammatory and Anti-fibrotic Activity in Multi-organ Fibrosis Preclinical Model

Thursday, December 2, 2021 - 6:31pm

SAN DIEGO, CA, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP or the Company), a clinical-stage biopharmaceutical company developing a new class of medicines to treat neurodegenerative, autoimmune and other diseases with unmet medical needs, has announced the publication of a scientific article in the peer-reviewed journal, Biomedicine & Pharmacotherapy, highlighting a new study providing additional data supporting the potential of EHP’s patented, first-in-class drug candidate, EHP-101, to treat fibrotic diseases, including cardiac fibrosis and systemic sclerosis (SSc). EHP is currently enrolling patients dosed with oral EHP-101 in a Phase IIa clinical trial for SSc (NCT04166552).

Key Points: 
  • The results of this new study indicate that EHP-101 could offer new opportunities in the treatment ofcardiac fibrosis and other fibrotic diseases.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates for the treatment of CNS, autoimmune, and other diseases.
  • Its second product candidate, EHP-102, is in preclinical development and is focused on treating Parkinsons disease and Huntingtons disease.
  • Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.

Coronavirus-3C-Like-Proteinase Inhibitors Pipeline Market Report 2021 - ResearchAndMarkets.com

Thursday, December 2, 2021 - 5:46pm

The "Coronavirus-3C-Like-Proteinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Coronavirus-3C-Like-Proteinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Coronavirus-3C-like-proteinase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Coronavirus-3C-like-proteinase inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Coronavirus-3C-like-proteinase inhibitors R&D.
  • This segment of the report provides insights about the different Coronavirus-3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

Hardman Talks | Oakley Capital Investments Webinar: Everything you wanted to know about private equity but were afraid to ask!

Thursday, December 2, 2021 - 11:03am

Hardman Talks | Oakley Capital Investments Webinar: Everything you wanted to know about private equity but were afraid to ask!

Key Points: 
  • Hardman Talks | Oakley Capital Investments Webinar: Everything you wanted to know about private equity but were afraid to ask!
  • Everything you wanted to know about private equity but were afraid to ask!
  • We will be hosting a live Q&A discussion on Hardman Talks featuring Steven Tredget, Oakley Capital Investments partner, and Mark Thomas, Hardman & Co Head of Investment Companies research.
  • Oakley Capital Investments provides investors with liquid access to the attractive PE market, enhanced by Oakley's incremental origination and management skills.

BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021

Thursday, December 2, 2021 - 8:00am

To learn more about BeiGenes research and development and activities at ESMO IO, please visit https://beigenemedical.eu/ .

Key Points: 
  • To learn more about BeiGenes research and development and activities at ESMO IO, please visit https://beigenemedical.eu/ .
  • Combination strategy is considered key to overcoming primary and acquired resistance to anti-PD-1 therapy and expanding clinical benefit of immunotherapy to more patients.
  • BeiGene is investigating the potential of novel tislelizumab combinations to drive stronger and more sustained tumor responses and impede tumor immune escape.
  • BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.

Institutional Investor Publishes 2021 Global Fixed-Income Research Rankings

Wednesday, December 1, 2021 - 4:30pm

This was the third year that Institutional Investor Research ran the fixed-income survey as a single Global ballot, rather than regionally.

Key Points: 
  • This was the third year that Institutional Investor Research ran the fixed-income survey as a single Global ballot, rather than regionally.
  • For over 50 years Institutional Investor has consistently distinguished itself among the worlds foremost media companies with ground-breaking journalism and incisive writing that provides essential intelligence for a global audience.
  • In addition, Institutional Investor offers highly respected proprietary benchmark research and rankings.
  • Institutional Investor Research (II Research) provides independent sell-side and corporate performance research and rankings and aims to be the first-choice and independent validation source of qualitative market intelligence for all three sides of the investment community.

DGAP-News: European Healthcare Acquisition & Growth Company B.V.: Former German healthcare leader of McKinsey & Company, Thomas Rudolph, takes office

Wednesday, December 1, 2021 - 2:25pm

There has been no, and will not be, public offering of the securities in the United States.

Key Points: 
  • There has been no, and will not be, public offering of the securities in the United States.
  • The Securities of EHC have not been, and will not be, registered under the Securities Act.
  • This publication constitutes neither an offer to sell nor a solicitation to buy securities.
  • The listing of the securities has been made solely by the means of, and on the basis of, the Prospectus.